CA2106172A1 - Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention - Google Patents
Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary InterventionInfo
- Publication number
- CA2106172A1 CA2106172A1 CA2106172A CA2106172A CA2106172A1 CA 2106172 A1 CA2106172 A1 CA 2106172A1 CA 2106172 A CA2106172 A CA 2106172A CA 2106172 A CA2106172 A CA 2106172A CA 2106172 A1 CA2106172 A1 CA 2106172A1
- Authority
- CA
- Canada
- Prior art keywords
- aminobenzoic acid
- treatment
- coronary intervention
- dimethoxycinnamoyl
- restenosis associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
This invention provides a pharmaceutical composition for the treatment or prevention of restenosis associated with coronary intervention, containing, as an active ingredient, 2-(3,4-dimethyoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof and the use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical for the treatment or prevention of restenosis associated with coronary intervention. A 600 mg dosage of 2-(3,4-dimethoxy-cinnamoyl)aminobenzoic acid for a treatment period of three consecutive months after coronary intervention lowers the incidence of restenosis, and reduces the degree of stenosis in patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4288086A JP2617407B2 (en) | 1992-09-14 | 1992-09-14 | Preventive and therapeutic agent for intimal cell hyperproliferative disease |
JP288086/92 | 1992-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2106172A1 true CA2106172A1 (en) | 1994-03-15 |
CA2106172C CA2106172C (en) | 2001-01-02 |
Family
ID=17725612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002106172A Expired - Fee Related CA2106172C (en) | 1992-09-14 | 1993-09-14 | Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment of restenosis associated with coronary intervention |
Country Status (7)
Country | Link |
---|---|
US (1) | US5385935A (en) |
EP (1) | EP0588518B1 (en) |
JP (1) | JP2617407B2 (en) |
KR (1) | KR100252410B1 (en) |
CA (1) | CA2106172C (en) |
DE (1) | DE69310065T2 (en) |
HK (1) | HK1005425A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994026303A1 (en) * | 1993-05-13 | 1994-11-24 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US5824644A (en) * | 1994-07-07 | 1998-10-20 | G. D. Searle & Co. | Method of attenuating arterial stenosis |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
CA2223595C (en) * | 1995-06-07 | 2008-08-05 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
CN1211182A (en) | 1996-02-15 | 1999-03-17 | 橘生药品工业株式会社 | Neovascularization inhibitor |
JPH09278653A (en) * | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | Retinal disease-treating preparation |
US6019104A (en) * | 1996-12-30 | 2000-02-01 | Kissei Pharmaceutical Co., Ltd. | Method for the treatment or prevention of restenosis associated with coronary intervention |
ATE240098T1 (en) * | 1997-02-14 | 2003-05-15 | Kissei Pharmaceutical | SUBSTANCES FOR INHIBITING THE FORMATION OF THE PTERYGIUM AND ITS POSTOPERATIVE RECURRENCE |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6303655B1 (en) * | 1997-04-18 | 2001-10-16 | Kissei Pharmaceutical Co., Ltd. | Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells |
ATE358456T1 (en) * | 1998-05-05 | 2007-04-15 | Boston Scient Ltd | STENT WITH SMOOTH ENDS |
PL351397A1 (en) * | 1999-02-03 | 2003-04-07 | Smithkline Beecham Corp | Method for the prevention or reduction of cariovascular events associated with coronary intervention |
BR0007901A (en) * | 1999-02-03 | 2001-10-30 | Smithkline Beecham Corp | Method for the preservation or reduction of cardiovascular events associated with coronary intervention |
DE60023008T2 (en) * | 1999-07-16 | 2006-07-06 | Kissei Pharmaceutical Co., Ltd., Matsumoto | MEANS TO PREVENT THE CHRONIC BREATHING REACTION AS A RESULT OF AN ORGANTRANSPLANTATION |
US6767544B2 (en) * | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
WO2001062241A1 (en) * | 2000-02-23 | 2001-08-30 | Smithkline Beecham Corporation | Method for the prevention or reduction of vascular access dysfunction |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
WO2004002367A1 (en) * | 2002-06-27 | 2004-01-08 | Microport Medical (Shanghai) Co., Ltd. | Drug eluting stent |
US20080306126A1 (en) * | 2004-01-05 | 2008-12-11 | Fonseca Vivian A | Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications |
US7473738B2 (en) * | 2004-09-30 | 2009-01-06 | Johnson & Johnson Vision Care, Inc. | Lactam polymer derivatives |
CN101652150B (en) * | 2006-12-01 | 2013-12-11 | 韦克福里斯特大学健康科学院 | Medical devices incorporating collagen inhibitors |
KR20120064067A (en) | 2009-06-17 | 2012-06-18 | 고꾸리쯔다이가꾸호오진 구마모또 다이가꾸 | Prophylactic and/or therapeutic agent for dysmenorrhea |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5640710B2 (en) * | 1973-01-18 | 1981-09-22 | ||
US4070484A (en) * | 1973-01-18 | 1978-01-24 | Kissei Pharmaceutical Co., Ltd. | Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same |
US4337270A (en) * | 1980-05-21 | 1982-06-29 | Hisamitsu Pharmaceutical Co., Inc. | Novel anthranilic acid derivatives |
-
1992
- 1992-09-14 JP JP4288086A patent/JP2617407B2/en not_active Expired - Fee Related
-
1993
- 1993-08-26 EP EP93306787A patent/EP0588518B1/en not_active Expired - Lifetime
- 1993-08-26 DE DE69310065T patent/DE69310065T2/en not_active Expired - Fee Related
- 1993-09-07 US US08/116,701 patent/US5385935A/en not_active Expired - Lifetime
- 1993-09-13 KR KR1019930018347A patent/KR100252410B1/en not_active IP Right Cessation
- 1993-09-14 CA CA002106172A patent/CA2106172C/en not_active Expired - Fee Related
-
1998
- 1998-05-27 HK HK98104564A patent/HK1005425A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100252410B1 (en) | 2000-05-01 |
JPH06135829A (en) | 1994-05-17 |
CA2106172C (en) | 2001-01-02 |
DE69310065D1 (en) | 1997-05-28 |
JP2617407B2 (en) | 1997-06-04 |
EP0588518A1 (en) | 1994-03-23 |
HK1005425A1 (en) | 1999-01-08 |
KR940006578A (en) | 1994-04-25 |
EP0588518B1 (en) | 1997-04-23 |
US5385935A (en) | 1995-01-31 |
DE69310065T2 (en) | 1997-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2106172A1 (en) | Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention | |
CA2105180A1 (en) | Compositions containing sumatriptan | |
CA2186039A1 (en) | New oral pharmaceutical dosage form | |
CA2065809A1 (en) | Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids | |
EP0513702A3 (en) | Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication | |
CA2125662A1 (en) | Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis | |
MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
CA2213700A1 (en) | Pharmaceutical composition for piperidinoalkanol compounds | |
RO116342B1 (en) | Oral liquid pharmaceutical composition | |
EP0375628A3 (en) | Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment | |
NO994165L (en) | Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness | |
EP0620004A4 (en) | Medicinal composition. | |
NO924066L (en) | THERAPEUTIC AGENT | |
JP2005511619A5 (en) | ||
CA2038744A1 (en) | Pharmaceutical composition containing slightly water-soluble drug | |
CA2180178A1 (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
CA2340734A1 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
UA40636C2 (en) | pharmaceutical composition containing, as the active ingredient, an association of acetylsalicylic acid and metoclopramide, pharmaceutical medication in the form of powder and method for its preparation | |
CA2120001A1 (en) | Flavopereirine-based pharmaceutical composition and use thereof for treating hiv | |
AR009446A1 (en) | USE OF 2- (3,4-DIMETOXINAMOIL) AMINOBENZOIC ACID (TRANILAST) IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF LARESTENOSIS, PHARMACEUTICAL COMPOSITION AND PREPARATION PROCEDURE. | |
EP0523013A3 (en) | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | |
DE69808287D1 (en) | PHARMACEUTICAL COMPOSITIONS OF CINCHONIN DIHYDROCHLORIDE | |
HUP0200148A2 (en) | Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention | |
IT1271354B (en) | Preparation of a pharmaceutical form capable of combating hyperinsulinism | |
HUP0200129A2 (en) | Use of n-(3'4'-dimethoxycinnamoyl) anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |